{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:49:15Z","timestamp":1779238155566,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/fpc.0000000000000020","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T09:31:01Z","timestamp":1384507861000},"page":"35-42","source":"Crossref","is-referenced-by-count":34,"title":["Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers"],"prefix":"10.1097","volume":"24","author":[{"given":"Kyoung-Ah","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jin","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"key":"R7-5-20210213","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates.","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"R8-5-20210213","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1081\/DMR-120001389","article-title":"Drugs as P-glycoprotein substrates, inhibitors, and inducers.","volume":"34","author":"Kim","year":"2002","journal-title":"Drug Metab Rev"},{"key":"R10-5-20210213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R14-5-20210213","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","article-title":"ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.","volume":"7","author":"Leschziner","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"R15-5-20210213","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.","volume":"37","author":"Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R16-5-20210213","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/clpt.2009.145","article-title":"Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.","volume":"86","author":"Kim","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R20-5-20210213","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0888-7543(03)00117-4","article-title":"Simultaneous screening for three mutations in the ABCB1 gene.","volume":"82","author":"Lotsch","year":"2003","journal-title":"Genomics"},{"key":"R21-5-20210213","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R22-5-20210213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/dmdi-2013-0008","article-title":"MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.","volume":"28","author":"Gonzalez-Vacarezza","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"R24-5-20210213","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.","volume":"7","author":"Wang","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R26-5-20210213","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics.","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R28-5-20210213","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-004-0853-x","article-title":"Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia.","volume":"60","author":"Li","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-5-20210213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17425255.2.2.171","article-title":"Clinical implications of CYP3A polymorphisms.","volume":"2","author":"Wojnowski","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R31-5-20210213","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2710.2009.01057.x","article-title":"Effect of CYP3A53 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.","volume":"34","author":"Park","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R32-5-20210213","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0091270006295063","article-title":"Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.","volume":"47","author":"Kim","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R35-5-20210213","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","article-title":"Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.","volume":"72","author":"Sparshatt","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R36-5-20210213","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":"Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R37-5-20210213","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R38-5-20210213","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity.","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:21:46Z","timestamp":1620951706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201401000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000020","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}